SMAD4 Antibody
Rabbit Polyclonal
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Background
This antibody is designed, produced, and validated as part of a collaboration between Rockland and the National Cancer Institute (NCI) and is suitable for Cancer, Immunology and Nuclear Signaling research. SMAD4 (also known as Mothers against decapentaplegic homolog 4, Mothers against DPP homolog 4, deletion target in pancreatic carcinoma 4 and hSMAD4) is a common mediator of signal transduction by TGF-b (transforming growth factor), but is also involved in cancer development and metastases as a tumor suppressor. SMAD4 promotes binding of the SMAD2/SMAD4/FAST-1 complex to DNA and provides an activation function required for SMAD1 or SMAD2 to stimulate transcription. SMAD4 may form trimers with receptor-regulated SMAD (R-SMAD) and interacts with ATF2, COPS5, DACH1, MSG1, SKI and TRIM33. In the absence of ligand SMAD4 is found in the cytoplasm, but when complexed with R-SMAD, translocates to the nucleus. Defects in SMAD4 are a cause of pancreatic carcinoma and juvenile polyposis syndrome (JPS), a syndrome in which patients are at risk for developing gastrointestinal cancers.
Product Details
Target Details
Application Details
Formulation
Shipping & Handling
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.